ArticleBMJ open ophthalmology2026

Phase 1 dose-escalation study of IBI324, a VEGF-A/Ang-2 bispecific antibody, for the treatment of diabetic macular oedema.

Zilin Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.